In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

From difficulties swallowing to tummy troubles, thousands of kids face digestive and eating challenges. For many families, the journey to understanding what’s wrong can be long and arduous, often ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...